Cargando…

(18)F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study

BACKGROUND: (18)F-fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-FDG PET-CT) is typically used to screen malignancy in patients with dermatomyositis (DM). The aim of this study was to investigate the value of using PET-CT in assessing the prognosis of patients with DM and...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yiduo, Wang, Bing, Zhang, Feifei, Wu, Min, Wang, Dongyan, Shao, Xiaoliang, Shao, Xiaonan, Wang, Jianfeng, Liu, Bao, Shi, Yunmei, Yu, Wenji, Wang, Yuetao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239996/
https://www.ncbi.nlm.nih.gov/pubmed/37284117
http://dx.doi.org/10.21037/qims-22-1174
_version_ 1785053639368245248
author Xu, Yiduo
Wang, Bing
Zhang, Feifei
Wu, Min
Wang, Dongyan
Shao, Xiaoliang
Shao, Xiaonan
Wang, Jianfeng
Liu, Bao
Shi, Yunmei
Yu, Wenji
Wang, Yuetao
author_facet Xu, Yiduo
Wang, Bing
Zhang, Feifei
Wu, Min
Wang, Dongyan
Shao, Xiaoliang
Shao, Xiaonan
Wang, Jianfeng
Liu, Bao
Shi, Yunmei
Yu, Wenji
Wang, Yuetao
author_sort Xu, Yiduo
collection PubMed
description BACKGROUND: (18)F-fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-FDG PET-CT) is typically used to screen malignancy in patients with dermatomyositis (DM). The aim of this study was to investigate the value of using PET-CT in assessing the prognosis of patients with DM and without malignant tumors. METHODS: A total of 62 patients with DM who underwent (18)F-FDG PET-CT were enrolled in the retrospective cohort study. Clinical data and laboratory indicators were obtained. The muscle max standardized uptake value (SUV(max)), splenic SUV(max), target-to-background ratio (TBR) of the aorta, pulmonary highest value (hv)/SUV(max), epicardial fat volume (EFV), and coronary artery calcium (CAC) were measured using (18)F-FDG PET-CT. The follow-up was conducted until March 2021, and the endpoint was death from any cause. Univariable and multivariable Cox regression analyses were used to analyze prognostic factors. The survival curves were produced with the Kaplan-Meier method. RESULTS: The median duration of follow-up was 36 [interquartile range (IQR), 14–53] months. The survival rates were 85.2% and 73.4% for 1 and 5 years, respectively. A total of 13 (21.0%) patients died during a median follow-up of 7 (IQR, 4–15.5) months. Compared with the survival group, the death group had significantly higher levels of C-reactive protein [CRP; median (IQR), 4.2 (3.0, 6.0) vs. 6.30 (3.7, 22.8)], hypertension [7 (14.3%) vs. 6 (46.2%)], interstitial lung disease [ILD; 26 (53.1%) vs. 12 (92.3%)], positive anti-Ro52 antibody [19 (38.8%) vs. 10 (76.9%)], pulmonary FDG uptake [median (IQR), 1.8 (1.5, 2.9) vs. 3.5 (2.0, 5.8)], CAC [1 (2.0%) vs. 4 (30.8%)], and EFV [median (IQR), 74.1 (44.8, 92.1) vs. 106.5 (75.0, 128.5)] (all P values <0.001). Univariable and multivariable Cox analyses identified high pulmonary FDG uptake [hazard ratio (HR), 7.59; 95% confidence interval (CI), 2.08–27.76; P=0.002] and high EFV (HR, 5.86; 95% CI, 1.77–19.42; P=0.004) as independent risk factors for mortality. The survival rate was significantly lower in patients with the concurrent presence of high pulmonary FDG uptake and high EFV. CONCLUSIONS: Pulmonary FDG uptake and EFV detected with PET-CT were independent risk factors for death in patients with DM and without malignant tumors. Patients with the concurrent presence of high pulmonary FDG uptake and high EFV had a worse prognosis compared with patients with 1 or neither of these two risk factors. Early treatment should be applied in patients with concurrent presence of high pulmonary FDG uptake and high EFV to improve the survival rate.
format Online
Article
Text
id pubmed-10239996
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-102399962023-06-06 (18)F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study Xu, Yiduo Wang, Bing Zhang, Feifei Wu, Min Wang, Dongyan Shao, Xiaoliang Shao, Xiaonan Wang, Jianfeng Liu, Bao Shi, Yunmei Yu, Wenji Wang, Yuetao Quant Imaging Med Surg Original Article BACKGROUND: (18)F-fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-FDG PET-CT) is typically used to screen malignancy in patients with dermatomyositis (DM). The aim of this study was to investigate the value of using PET-CT in assessing the prognosis of patients with DM and without malignant tumors. METHODS: A total of 62 patients with DM who underwent (18)F-FDG PET-CT were enrolled in the retrospective cohort study. Clinical data and laboratory indicators were obtained. The muscle max standardized uptake value (SUV(max)), splenic SUV(max), target-to-background ratio (TBR) of the aorta, pulmonary highest value (hv)/SUV(max), epicardial fat volume (EFV), and coronary artery calcium (CAC) were measured using (18)F-FDG PET-CT. The follow-up was conducted until March 2021, and the endpoint was death from any cause. Univariable and multivariable Cox regression analyses were used to analyze prognostic factors. The survival curves were produced with the Kaplan-Meier method. RESULTS: The median duration of follow-up was 36 [interquartile range (IQR), 14–53] months. The survival rates were 85.2% and 73.4% for 1 and 5 years, respectively. A total of 13 (21.0%) patients died during a median follow-up of 7 (IQR, 4–15.5) months. Compared with the survival group, the death group had significantly higher levels of C-reactive protein [CRP; median (IQR), 4.2 (3.0, 6.0) vs. 6.30 (3.7, 22.8)], hypertension [7 (14.3%) vs. 6 (46.2%)], interstitial lung disease [ILD; 26 (53.1%) vs. 12 (92.3%)], positive anti-Ro52 antibody [19 (38.8%) vs. 10 (76.9%)], pulmonary FDG uptake [median (IQR), 1.8 (1.5, 2.9) vs. 3.5 (2.0, 5.8)], CAC [1 (2.0%) vs. 4 (30.8%)], and EFV [median (IQR), 74.1 (44.8, 92.1) vs. 106.5 (75.0, 128.5)] (all P values <0.001). Univariable and multivariable Cox analyses identified high pulmonary FDG uptake [hazard ratio (HR), 7.59; 95% confidence interval (CI), 2.08–27.76; P=0.002] and high EFV (HR, 5.86; 95% CI, 1.77–19.42; P=0.004) as independent risk factors for mortality. The survival rate was significantly lower in patients with the concurrent presence of high pulmonary FDG uptake and high EFV. CONCLUSIONS: Pulmonary FDG uptake and EFV detected with PET-CT were independent risk factors for death in patients with DM and without malignant tumors. Patients with the concurrent presence of high pulmonary FDG uptake and high EFV had a worse prognosis compared with patients with 1 or neither of these two risk factors. Early treatment should be applied in patients with concurrent presence of high pulmonary FDG uptake and high EFV to improve the survival rate. AME Publishing Company 2023-03-30 2023-06-01 /pmc/articles/PMC10239996/ /pubmed/37284117 http://dx.doi.org/10.21037/qims-22-1174 Text en 2023 Quantitative Imaging in Medicine and Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Xu, Yiduo
Wang, Bing
Zhang, Feifei
Wu, Min
Wang, Dongyan
Shao, Xiaoliang
Shao, Xiaonan
Wang, Jianfeng
Liu, Bao
Shi, Yunmei
Yu, Wenji
Wang, Yuetao
(18)F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study
title (18)F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study
title_full (18)F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study
title_fullStr (18)F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study
title_full_unstemmed (18)F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study
title_short (18)F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study
title_sort (18)f-fdg pet-ct for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239996/
https://www.ncbi.nlm.nih.gov/pubmed/37284117
http://dx.doi.org/10.21037/qims-22-1174
work_keys_str_mv AT xuyiduo 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT wangbing 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT zhangfeifei 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT wumin 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT wangdongyan 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT shaoxiaoliang 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT shaoxiaonan 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT wangjianfeng 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT liubao 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT shiyunmei 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT yuwenji 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy
AT wangyuetao 18ffdgpetctforthepredictionofmortalityinpatientswithdermatomyositisandwithoutmalignanttumorsapilotstudy